Wip1 Phosphatase Modulates ATM-Dependent Signaling Pathways

Molecular Cell

Volumn 23, Issue 5, 2006, Pages 757-764

  Shreeram, Sathyavageeswaran ^a   Demidov, Oleg N ^a   Hee, Weng Kee ^a   Yamaguchi, Hiroshi ^b   Onishi, Nobuyuki ^c   Kek, Calvina ^a   Timofeev, Oleg N ^a   Dudgeon, Crissy ^b   Fornace, Albert J ^d   Anderson, Carl W ^e   Minami, Yasuhiro ^c   Appella, Ettore ^b   Bulavin, Dmitry V ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NATIONAL CANCER INSTITUTE   (United States)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

DNA; SIGNALING

Indexed keywords

ATM PROTEIN; DNA; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PHOSPHATASE WIP 1; SERINE; UNCLASSIFIED DRUG;

ARTICLE; ATAXIA TELANGIECTASIA; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; ENZYME DEFICIENCY; ENZYME REGULATION; ENZYME SUBSTRATE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL CYCLE PROTEINS; DNA DAMAGE; DNA-BINDING PROTEINS; HELA CELLS; HUMANS; KINETICS; MICE; NEOPLASM PROTEINS; PHOSPHOPEPTIDES; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; PHOSPHOSERINE; PROTEIN-SERINE-THREONINE KINASES; RADIATION, IONIZING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 33748150967     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2006.07.010     Document Type: Article

References (33)

1. Alt J.R., Greiner T.C., Cleveland J.L., and Eischen C.M. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 22 (2003) 1442-1450
2. Bakkenist C.J., and Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421 (2003) 499-506
3. Barlow C., Hirotsune S., Paylor R., Liyanage M., Eckhaus M., Collins F., Shiloh Y., Crawley J.N., Ried T., Tagle D., and Wynshaw-Boris A. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86 (1996) 159-171
4. Belova G.I., Demidov O.N., Fornace A.J., and Bulavin D.V. Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biol. Ther. 4 (2005) 1154-1158
5. Bond G.L., Hirshfield K.M., Kirchhoff T., Alexe G., Bond E.E., Robins H., Bartel F., Taubert H., Wuerl P., Hait W., et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 66 (2006) 5104-5110
6. Bulavin D.V., Saito S., Hollander M.C., Sakaguchi K., Anderson C.W., Appella E., and Fornace Jr. A.J. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18 (1999) 6845-6854
7. Bulavin D.V., Demidov O.N., Saito S., Kauraniemi P., Phillips C., Amundson S.A., Ambrosino C., Sauter G., Nebreda A.R., Anderson C.W., et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet. 31 (2002) 210-215
8. Arf pathway. Nat. Genet. 36 (2004) 343-350
9. Fiscella M., Zhang H., Fan S., Sakaguchi K., Shen S., Mercer W.E., Vande Woude G.F., O'Connor P.M., and Appella E. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc. Natl. Acad. Sci. USA 94 (1997) 6048-6053
10. Fujimoto H., Onishi N., Kato N., Takekawa M., Xu X.Z., Kosugi A., Kondo T., Oishi I., Yoda A., Imamura M., and Minami Y. Regulation of the anti-oncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ. 13 (2006) 1170-1180
11. Goodarzi A.A., Jonnalagadda J.C., Douglas P., Young D., Ye R., Moorhead G.B., Lees-Miller S.P., and Khanna K.K. Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J. 23 (2004) 4451-4461
12. Gumy-Pause F., Wacker P., and Sappino A.-P. ATM gene and lymphoid malignancies. Leukemia 18 (2004) 238-242
13. Hirasawa A., Saito-Ohara F., Inoue J., Aoki D., Susumu N., Yokoyama T., Nozawa S., Inazawa J., and Imoto I. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin. Cancer Res. 9 (2003) 1995-2004
14. Kallioniemi A., Kallioniemi O.-P., Piper J., Tanner M., Stokke T., Chen L., Smith H.S., Pinkel D., Gray J.W., and Waldman F.M. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc. Natl. Acad. Sci. USA 91 (1994) 2156-2160
15. Kastan M.B., and Bartek J. Cell-cycle checkpoints and cancer. Nature 432 (2004) 316-323
16. Khan J., Parsa N.Z., Harada T., Meltzer P.S., and Carter N.P. Detection of gains and losses in 18 meningiomas by comparative genomic hybridization. Cancer Genet. Cytogenet. 103 (1998) 95-100
17. Lavin M.F., Delia D., and Chessa L. ATM and the DNA damage response. Workshop on ataxia-telangiectasia and related syndromes. EMBO Rep. 7 (2006) 154-160
18. Lee J.H., and Paull T.T. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science 304 (2004) 93-96
19. Li J., Yang Y., Peng Y., Austin R.J., van Eyndhoven W.G., Nguyen K.C.Q., Gabriele T., McCurrach M.E., Marks J.R., Hoey T., et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat. Genet. 31 (2002) 133-134
20. Lu X., Nannenga B., and Donehower L.A. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 19 (2005) 1162-1174
21. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., and Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362 (1993) 857-860
22. Plantaz D., Mohapatra G., Matthay K.K., Pellarin M., Seeger R., and Feuerstein B.G. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am. J. Pathol. 150 (1997) 81-89
23. Ried T., Petersen I., Holtgreve-Grez H., Speicher M.R., Schrock E., du Manoir S., and Cremer T. Mapping of multiple DNA gains and losses in primary small cell lung carcinomas by comparative genomic hybridization. Cancer Res. 54 (1994) 1801-1806
24. Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., and Inazawa J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 63 (2003) 1876-1883
25. Shiloh Y., and Kastan M.B. ATM: genome stability, neuronal development, and cancer cross paths. Adv. Cancer Res. 83 (2001) 209-254
26. Solinas-Toldo S., Wallrapp C., Muller-Pillasch F., Bentz M., Gress T., and Lichter P. Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res. 56 (1996) 3803-3807
27. Sun Y., Jiang X., Chen S., Fernandes N., and Price B.D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc. Natl. Acad. Sci. USA 102 (2005) 13182-13187
28. Takekawa M., Adachi M., Nakahata A., Nakayama I., Itoh F., Tsukuda H., Taya Y., and Imai K. p53-inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J. 19 (2000) 6517-6526
29. Voncken J.W., Niessen H., Neufeld B., Rennefahrt U., Dahlmans V., Kubben N., Holzer B., Ludwig S., and Rapp U.R. MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1. J. Biol. Chem. 280 (2005) 5178-5187
30. Voorter C., Joos S., Bringuier P.P., Vallinga M., Poddighe P., Schalken J., du Manoir S., Ramaekers F., Lichter P., and Hopman A. Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am. J. Pathol. 146 (1995) 1341-1354
31. Wong N., Lai P., Lee S.-W., Fan S., Pang E., Liew C.-T., Sheng Z., Lau J.W.-Y., and Johnson P.J. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am. J. Pathol. 154 (1999) 37-43
32. Xu Y., Ashley T., Brainerd E.E., Bronson R.T., Meyn M.S., and Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10 (1996) 2411-2422
33. Yamaguchi H., Minopoli G., Demidov O.N., Chatterjee D.K., Anderson C.W., Durell S.R., and Appella E. Substrate specificity of the human protein phosphatase 2Cδ, Wip1. Biochemistry 44 (2005) 5285-5294